Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01375699 · ClinicalTrials.gov registry record · Phase 1
Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01375699 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 26 participants.
The verdict
NCT01375699, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Sildenafil increases the therapeutic effect of doxorubicin used as treatment for cancers of solid tumors through both an increase in anti-tumor effects and protection from cardiac toxicity.
Interventions
- DRUG Doxorubicin
- DRUG Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-08-11 |
| Est. Completion | 2018-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01375699
The ClinicalTrials.gov registry entry for NCT01375699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxorubicin is the first listed.
NCT01375699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01375699 about?
NCT01375699 is a clinical study titled "Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers". Sildenafil increases the therapeutic effect of doxorubicin used as treatment for cancers of solid tumors through both an increase in anti-tumor effects and protection from cardiac toxicity.
What is the current status of trial NCT01375699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2011-08-11. Estimated completion is 2018-01-19.
What interventions are being tested in trial NCT01375699?
The interventions under investigation include: Doxorubicin (DRUG), Sildenafil (DRUG).
Who is sponsoring clinical trial NCT01375699?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.